
Jazz Pharmaceuticals and AbCellera Partner on GI Cancer Drug Discovery
Jazz Pharmaceuticals is betting $56 million in upfront payments on AbCellera’s antibody discovery engine to hunt for next-generation T-cell engaging treatments. The deal, announced June 17, 2026, marks a strategic push by Jazz to expand its oncology portfolio with specialized therapies aimed at gastrointestinal cancers and other solid tumors.



























